Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Polmacoxib (CG 100649) is a first-in-class NSAID drug candidate, is a dual inhibitor of carbonic anhydrase (CA) and COX-2. Polmacoxib inhibits premalignant and malignant colorectal lesions in mouse models, partly through inhibiting tumor cell proliferation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 109.00 | |
25 mg | In stock | $ 183.00 | |
50 mg | In stock | $ 272.00 | |
100 mg | In stock | $ 397.00 | |
200 mg | In stock | $ 593.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | Polmacoxib (CG 100649) is a first-in-class NSAID drug candidate, is a dual inhibitor of carbonic anhydrase (CA) and COX-2. Polmacoxib inhibits premalignant and malignant colorectal lesions in mouse models, partly through inhibiting tumor cell proliferation. |
Targets&IC50 | COX-2:0.1 μg/mL (IC50) |
Synonyms | CG-100649, CG100649, CG 100649 |
Molecular Weight | 361.39 |
Formula | C18H16FNO4S |
CAS No. | 301692-76-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 55 mg/ml (152.19 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Polmacoxib 301692-76-2 Immunology/Inflammation Metabolism Neuroscience COX Carbonic Anhydrase NSAID inflammatory polyp colorectal adenoma tumor Inhibitor CG-100649 Cyclooxygenase inhibit Carbonate dehydratase CG100649 orthotopic CG 100649 inhibitor